For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable.
Desjardins Securities analyst Chris MacCulloch downgraded seven Canadian energy companies on Wednesday after making a ...
An expert discusses how medical professionals monitor and manage adverse events (AEs) with adjuvant nivolumab through regular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback